Welcome to our dedicated page for Akebia Therapeut news (Ticker: AKBA), a resource for investors and traders seeking the latest updates and insights on Akebia Therapeut stock.
Akebia Therapeutics, Inc. (AKBA) is a biopharmaceutical leader developing innovative therapies for kidney disease, including FDA-approved Auryxia® and investigational oral HIF inhibitor Vafseo™. This page provides authorized updates on clinical developments, regulatory milestones, and strategic initiatives shaping renal care.
Access Akebia's official press releases covering phase 3 trial results, regulatory submissions, and commercial partnerships with dialysis providers. Investors will find timely updates on financial performance, including earnings calls and SEC filings related to anemia treatment innovations.
Our curated news collection helps stakeholders track progress in HIF biology applications and chronic kidney disease management. Bookmark this page for verified updates on product approvals, research collaborations, and market expansion strategies directly from Akebia Therapeutics.
Akebia Therapeutics (Nasdaq: AKBA) has announced the commencement of an underwritten public offering of common stock. The company plans to grant underwriters a 30-day option to purchase up to an additional 15% of shares at the public offering price, less underwriting discounts and commissions.
The offering will be managed jointly by Leerink Partners and Piper Sandler & Co. as bookrunning managers. The shares are being offered through a shelf registration statement filed with the SEC on September 3, 2024, and declared effective on September 12, 2024.
The offering's final terms will be disclosed in a final prospectus supplement to be filed with the SEC. The completion, size, and terms of the offering are subject to market conditions.
Akebia Therapeutics (AKBA) reported its Q4 and full-year 2024 financial results, highlighting the successful launch of Vafseo® (vadadustat) in January 2025. The company expects Q1 2025 Vafseo net product revenues of $10-$11 million.
Key financial metrics for Q4 2024 include:
- Total revenues: $46.5M (down from $56.2M in Q4 2023)
- Auryxia® net product revenues: $44.4M (down from $53.2M)
- Net loss: $22.8M (compared to $0.6M net income in Q4 2023)
- Cash position: $51.9M as of December 31, 2024
The company secured commercial supply contracts with dialysis organizations covering nearly 100% of U.S. dialysis patients. Over 500 prescribers have written prescriptions for Vafseo, averaging 8 prescriptions each. Akebia plans to initiate the Phase 3 VALOR trial for non-dialysis CKD patients in H2 2025 and expects current cash resources to fund operations for at least two years.
Akebia Therapeutics (Nasdaq: AKBA) has scheduled the release of its fourth quarter and full year 2024 financial results on Thursday, March 13, 2025, before market open. The company will host a conference call at 8:00 a.m. ET on the same day to discuss the financial performance and recent business developments.
Investors and interested parties can access the conference call through a registration link, with recommended dial-in 15 minutes before the scheduled start time. A live webcast will be available through the Investors section of Akebia's website, with an online archive accessible afterward at ir.akebia.com.
Akebia Therapeutics (Nasdaq: AKBA) has granted stock options to two newly-hired employees as part of their employment inducement package. The grants, issued on February 28, 2025, total 13,525 shares of common stock with an exercise price of $1.85 per share, matching the closing price on the grant date.
The options are structured with a four-year vesting schedule, where 25% of shares vest after the first year, followed by quarterly vesting of the remaining 75%. These 10-year term options were granted under Nasdaq Listing Rule 5635(c)(4) and are subject to Akebia's inducement award program terms and conditions.
Akebia Therapeutics (AKBA) has granted stock options to seven newly-hired employees as part of their employment inducement package. The options allow for the purchase of a total of 130,763 shares of Akebia's common stock at an exercise price of $2.24 per share, matching the closing price on January 31, 2025.
The options feature a four-year vesting schedule, with 25% vesting after the first year and the remaining 75% vesting quarterly thereafter, contingent on continued employment. Each option has a 10-year term and falls under Akebia's inducement award program, complying with Nasdaq Listing Rule 5635(c)(4).
Akebia Therapeutics (NASDAQ: AKBA) announced significant business updates regarding Vafseo® (vadadustat), its treatment for anemia in chronic kidney disease (CKD) patients on dialysis. The company has secured commercial supply contracts covering nearly 100% of U.S. dialysis patients and commenced product shipments in January 2025.
Market research indicates strong physician interest, with 99% of nephrologists considering prescribing Vafseo and 75% planning to do so within 6 months. The company plans to expand Vafseo's label through a Phase 3 trial for non-dialysis CKD patients, starting mid-2025, targeting a potential billion-dollar market opportunity.
U.S. Renal Care has enrolled over 650 patients in the VOICE clinical trial. Akebia confirms its current cash resources will fund operations, including the U.S. launch and pipeline development, for at least two years.
Akebia Therapeutics (AKBA) has granted stock options to one newly-hired employee as part of their employment inducement package. The grant, issued on December 31, 2024, consists of options to purchase 3,000 shares of Akebia's common stock at an exercise price of $1.90 per share, matching the closing price on the grant date.
The options feature a four-year vesting schedule, with 25% vesting after the first year and the remaining 75% vesting quarterly thereafter, contingent on continued employment. The options have a 10-year term and are subject to Akebia's inducement award program terms. This grant was made in accordance with Nasdaq Listing Rule 5635(c)(4).
Akebia Therapeutics (Nasdaq: AKBA) has announced its participation in the 43rd Annual J.P. Morgan Healthcare Conference. CEO John Butler will deliver a presentation on Thursday, January 16, 2024, at 7:30 AM PST, which will include updates on the Vafseo® (vadadustat) U.S. launch and other business matters. The conference is scheduled for January 13-16, 2025, in San Francisco. Interested parties can access the presentation webcast through the 'Investors' section of Akebia's website after the conference.
Akebia Therapeutics (Nasdaq: AKBA) has granted stock options to nine newly-hired employees on November 29, 2024. The inducement grants total 121,000 shares of common stock with an exercise price of $2.06 per share, matching the closing price on the grant date. The options follow a four-year vesting schedule with 25% vesting after the first year and the remaining 75% vesting quarterly thereafter, contingent on continued employment. These 10-year term options were granted under Nasdaq Listing Rule 5635(c)(4) as part of Akebia's inducement award program.
Akebia Therapeutics (Nasdaq: AKBA) announced that U.S. Renal Care has enrolled the first patients in the VOICE collaborative trial for Vafseo (vadadustat). The study will evaluate Vafseo's safety and efficacy when administered three times weekly to dialysis patients, comparing it to standard-of-care treatments. The trial aims to enroll approximately 2,200 patients and will assess non-inferiority for all-cause mortality as primary endpoint and superiority in reducing all-cause hospitalization as secondary endpoint. Vafseo, approved by the FDA in March 2024 for anemia in CKD patients on dialysis, is expected to launch in January 2025.
FAQ
What is the current stock price of Akebia Therapeut (AKBA)?
What is the market cap of Akebia Therapeut (AKBA)?
